Clinical-Grade Supply Infrastructure
The supply chain you inherited wasn't built for this.
Late certificates of analysis. Inconsistent batch purity. Opaque sourcing that puts your regulatory standing at risk. You already know the operational drag of babysitting suppliers who promise clinical-grade but deliver compliance grey areas. This isn't an industry failing — it's a structural gap that was never closed.
The Regulatory Reckoning Is Already Here
The enforcement environment across FDA, TGA, and state-level regulators has shifted from advisory to operational. Grey-market channels and RUO-pathway suppliers that once operated in ambiguity are being systematically closed. The correction isn't coming — it's underway.
FDA Category 2 Peptide Classifications
Reclassification of key peptide compounds under Category 2 has narrowed the legal pathway for bulk API sourcing, requiring demonstrable cGMP compliance at every node in the supply chain.
TGA Safety Advisories on Unapproved Peptides
The Therapeutic Goods Administration has issued targeted advisories flagging unapproved peptide products, signalling accelerated enforcement against unregistered supply channels entering Australia.
Rising CBP Customs Seizure Rates
U.S. Customs and Border Protection has increased interception of undocumented bioactive shipments by over 300% since 2022, with seizure data now shared across international enforcement networks.
State Board Enforcement Actions
Multiple state pharmacy boards have initiated disciplinary proceedings against practitioners sourcing from non-compliant suppliers — shifting liability from the vendor to the prescriber.
Documentation Standards Are the New Baseline
Certificates of Analysis, chain-of-custody records, and batch-level traceability are no longer differentiators — they're the minimum threshold for regulatory defensibility.
We Built the Infrastructure the Supply Chain Was Missing
mCare is the upstream bioactive supply partner for licensed distributors, compounding pharmacies, and clinical institutions. We are not a marketplace or a catalogue — we are supply chain infrastructure, purpose-built for regulated markets.
We exist because the professionals responsible for patient outcomes should never have to second-guess their supply inputs. Every capability was designed to remove friction, ambiguity, and risk from the procurement of high-specification compounds.
Verified Upstream Supplier Relationships
Built over years, not sourced opportunistically. Every supplier undergoes rigorous qualification before a single gram enters our chain of custody.
Cross-Border Cold-Chain Logistics
Documented customs clearance capability with our Real-Time Shipment Traceability Portal — giving partners live shipment status, temperature logs, and documentation readiness before delivery.
Compliance Documentation Infrastructure
Satisfies pharmacopeial standards proactively on every shipment — not reactively on request. COAs, stability data, and regulatory filings travel with the product, not after it.
What We Stand Behind
These are not aspirational statements. They are operational constraints we enforce on ourselves — the non-negotiable architecture of every decision, every shipment, every partnership.
Uncompromised Purity
Every compound meets or exceeds pharmacopeial standards. There are no tiers, no "good enough" grades, no exceptions for urgency or volume. If it doesn't pass, it doesn't ship.
Full Traceability
Every step from source to delivery is documented and verifiable. Batch-level Certificates of Analysis accompany every shipment as baseline — not as a premium feature you negotiate for.
Supply Chain Integrity
Infrastructure, not shortcuts. Verified upstream relationships, cold-chain logistics, and customs clearance capability built into every supply pathway — because reliability is engineered, not improvised.
Professional Trust
Earned through consistency, not promises. Our Catalogue Expansion Intelligence system uses partner demand signals to proactively expand the standard catalogue — your needs shape what we build next.
Regulatory Alignment
We operate to the standards that regulated markets demand — proactively. Partner Intelligence Briefings alert you to regulatory changes before they impact your operations, not after.
Accountability
If it ships under our name, we stand behind it completely. No hedging, no disclaimers designed to diffuse responsibility. One standard, one name, one line of accountability.
What we will never do
Your Next Step
Begin With Certainty
Whether you're a distribution partner evaluating upstream sources, a compounding pharmacy seeking defensible supply, or a research institution requiring reproducible-grade compounds — every relationship starts with proof, not promises.
No commitment required. The first step is a conversation.